Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus
Eli Lilly shares rose 4.1% to $1,108.09 after the company agreed to acquire Ventyx Biosciences for $1.2 billion in cash. Ventyx holders will receive $14 per share, a 62% premium to its 30-day VWAP. The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval. Lilly also announced a multi-year obesity drug partnership with Nimbus Therapeutics.
